Ginkgo Bioworks Holdings, Inc.: CASCADE INVESTMENT, L.L.C. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Cascade Investment, L.L.C. amended its Schedule 13G filing on Ginkgo Bioworks Holdings, Inc., updating its beneficial ownership stake in the synthetic biology company, per SEC accession 0001104659-26-128348. The filing is a passive-investor disclosure rather than an activist position, and the amended document did not disclose a change in share count in the headline. The update matters because Cascade, the investment vehicle tied to Bill Gates, is a notable institutional holder, and 13G amendments are watched for signals of stake building or trimming. Investors will look to the filing's detailed holdings figures for the direction and size of any change, and to future 13G or 13D filings for further shifts.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Ginkgo Bioworks Holdings, Inc., CASCADE INVESTMENT, L.L.C.